Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia
The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who c...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2001]
|
| In: |
Leukemia and lymphoma
Year: 2001, Jahrgang: 42, Heft: 3, Pages: 551-553 |
| ISSN: | 1029-2403 |
| DOI: | 10.3109/10428190109064616 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3109/10428190109064616
|
| Verfasserangaben: | G. Egerer, K. Sauerland & A.D. Ho (Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Universityof Heidelberg) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1782638938 | ||
| 003 | DE-627 | ||
| 005 | 20220820100210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211221s2001 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/10428190109064616 |2 doi | |
| 035 | |a (DE-627)1782638938 | ||
| 035 | |a (DE-599)KXP1782638938 | ||
| 035 | |a (OCoLC)1341436555 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 245 | 1 | 0 | |a Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia |c G. Egerer, K. Sauerland & A.D. Ho (Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Universityof Heidelberg) |
| 264 | 1 | |c [2001] | |
| 300 | |b 1 Diagramm | ||
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druckausgabe | ||
| 500 | |a Gesehen am 21.12.2021 | ||
| 520 | |a The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who cannot tolerate chemotherapy because of marrow aplasia. We observed a continuous complete remission induced by rituximab alone in a 72 year old patients with refractory and progressive high-grade non-Hodgkin's lymphoma (NHL) in the phase of chemotherapy induced marrow aplasia. | ||
| 650 | 4 | |a bone marrow aplasia | |
| 650 | 4 | |a non-Hodgkin's lymphoma | |
| 650 | 4 | |a Rituximab | |
| 700 | 1 | |a Sauerland, Katrin |d 1969- |e VerfasserIn |0 (DE-588)122371410 |0 (DE-627)705882349 |0 (DE-576)293241732 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 42(2001), 3, Seite 551-553 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia |
| 773 | 1 | 8 | |g volume:42 |g year:2001 |g number:3 |g pages:551-553 |g extent:3 |a Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia |
| 856 | 4 | 0 | |u https://doi.org/10.3109/10428190109064616 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211221 | ||
| 993 | |a Article | ||
| 994 | |a 2001 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 3 |y j | ||
| 998 | |g 122371410 |a Sauerland, Katrin |m 122371410:Sauerland, Katrin |d 910000 |d 910100 |e 910000PS122371410 |e 910100PS122371410 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |e 910000PE105502168X |e 910100PE105502168X |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1782638938 |e 4023452130 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["G. Egerer, K. Sauerland & A.D. Ho (Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Universityof Heidelberg)"]},"origin":[{"dateIssuedDisp":"[2001]","dateIssuedKey":"2001"}],"id":{"doi":["10.3109/10428190109064616"],"eki":["1782638938"]},"physDesc":[{"extent":"3 S.","noteIll":"1 Diagramm"}],"relHost":[{"pubHistory":["1.1989/90 -"],"part":{"year":"2001","issue":"3","pages":"551-553","text":"42(2001), 3, Seite 551-553","volume":"42","extent":"3"},"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 08.09.15"],"disp":"Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasiaLeukemia and lymphoma","language":["eng"],"recId":"324746237","title":[{"title_sort":"Leukemia and lymphoma","title":"Leukemia and lymphoma"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedDisp":"1989-","dateIssuedKey":"1989","publisher":"Taylor & Francis Group ; Informa Healthcare"}],"id":{"zdb":["2030637-4"],"eki":["324746237"],"issn":["1029-2403"]}}],"person":[{"display":"Egerer, Gerlinde","roleDisplay":"VerfasserIn","role":"aut","family":"Egerer","given":"Gerlinde"},{"family":"Sauerland","given":"Katrin","roleDisplay":"VerfasserIn","display":"Sauerland, Katrin","role":"aut"},{"family":"Ho","given":"Anthony Dick","display":"Ho, Anthony Dick","roleDisplay":"VerfasserIn","role":"aut"}],"title":[{"title_sort":"Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia","title":"Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia"}],"note":["Elektronische Reproduktion der Druckausgabe","Gesehen am 21.12.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1782638938","language":["eng"]} | ||
| SRT | |a EGERERGERLREMARKABLE2001 | ||